<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668796</url>
  </required_header>
  <id_info>
    <org_study_id>GLK-1502</org_study_id>
    <nct_id>NCT02668796</nct_id>
  </id_info>
  <brief_title>To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.</brief_title>
  <official_title>A Phase III Investigator-Blind, Randomized, Parallel-Group, Placebo- Controlled, Multicentre Study to Evaluate the Therapeutic Equivalence and Safety of Estradiol Vaginal Tablets 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk Inc.) Administered for 14 Days and Compare Both Active Treatments to a Placebo Control in Female Subjects With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated With Menopause.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, Parallel-Group, Placebo- Controlled, Multicenter Study to Evaluate the
      Therapeutic Equivalence and Safety of Estradiol Vaginal Tablets 10 mcg and Vagifem®
      (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk Inc.) in Female Subjects with Moderate to
      Severe Symptoms of Vulvar and Vaginal Atrophy Associated with Menopause.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">September 21, 2016</completion_date>
  <primary_completion_date type="Actual">September 21, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with at least 25% reduction from baseline in the sum of % basal/parabasal + %intermediate cells on vaginal cytology and vaginal pH &lt;5.0 with a change from baseline vaginal pH of at least 0.5</measure>
    <time_frame>Day 15]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with treatment success at the end of study where treatment success is defined as a subject who achieves a score of 0 (none) or 1 (mild) at Visit 3/End of Study for the MBS</measure>
    <time_frame>Day 15]</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">522</enrollment>
  <condition>Vulvar and Vaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Estradiol Vaginal Tablets 10 mcg (Glenmark)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apply using the given applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apply using the given applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>apply using the given applicator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Vaginal Tablets 10 mcg (Glenmark)</intervention_name>
    <description>apply using the given applicator</description>
    <arm_group_label>Estradiol Vaginal Tablets 10 mcg (Glenmark)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)</intervention_name>
    <description>apply using the given applicator</description>
    <arm_group_label>Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)</intervention_name>
    <description>apply using the given applicator</description>
    <arm_group_label>Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female postmenopausal subjects aged &gt;30 to &lt;75 years

          2. At least 1 subject assessed moderate to severe symptom of vulvar and vaginal atrophy
             among the following that is identified as being the most bothersome to her

               -  vaginal dryness

               -  vaginal and/or vulvar irritation/ itching

               -  dysuria

               -  vaginal pain associated with sexual activity

               -  presence of vaginal bleeding associated with sexual activity

          3. Have &lt;5% superficial cells on vaginal smear cytology and vaginal pH &gt;5.0 at Visit 1

          4. Systolic blood pressure &lt;150mm Hg and diastolic blood pressure &lt;90mm Hg at Visit 1

        Exclusion Criteria:

          1. Known hypersensitivity to Estradiol vaginal tablet

          2. Screening mammogram or clinical breast examination results indicating any suspicion of
             breast malignancy.

          3. History of undiagnosed vaginal bleeding.

          4. History of significant risk factors for endometrial cancer

          5. For women with an intact uterus, screening vaginal ultrasonography showing endometrial
             thickness of ≥ 4 mm.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Nikhil Sawant</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glenmark Pharmaceuticals Inc.</name>
      <address>
        <city>Mahwah</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

